We use patented CRISPR technology to produce non-addictive opiates for pain management in collaboration with Merck Pharmaceuticals Germany
Emerzene Inc has raised $5.3M in total funding. The most recent round was Pre-Seed. The last funding was announced in December 2021.
Emerzene Inc is headquartered in Dublin, Ireland.
We use patented CRISPR technology to produce non-addictive opiates for pain management in collaboration with Merck Pharmaceuticals Germany
Emerzene Inc is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Emerzene Inc — Funding & Investors." VCBacked, December 24, 2021, https://www.vcbacked.co/company/emerzene-inc. Accessed August 16, 2026.
VCBacked. (2021). Emerzene Inc — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/emerzene-inc
{{cite web |title=Emerzene Inc — Funding & Investors |url=https://www.vcbacked.co/company/emerzene-inc |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated